^
    1d
    CASPAR: A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (clinicaltrials.gov)
    P3, N=61, Active, not recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial primary completion date
    |
    Xtandi (enzalutamide) • Rubraca (rucaparib) • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension
    1d
    Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, Shanghai Changzheng Hospital
    New P1 trial
    |
    Xtandi (enzalutamide) • triptorelin • goserelin acetate
    1d
    Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Shanghai Changzheng Hospital
    New P1 trial
    |
    Tevimbra (tislelizumab-jsgr) • triptorelin • goserelin acetate
    3d
    EndomMASLD: Effect of a GnRH Analog on Hepatic Steatosis (clinicaltrials.gov)
    P4, N=62, Recruiting, Aristotle University Of Thessaloniki | Trial completion date: Apr 2027 --> Oct 2027 | Trial primary completion date: Oct 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    LEP (Leptin)
    |
    goserelin acetate
    7d
    Multidimensional evaluation of different dosage forms of goserelin in the treatment of premenopausal HR+ breast cancer patients based on real-world data (ChiCTR2500112684)
    P=N/A, N=200, Recruiting, First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital of Zhengzhou University
    New trial
    |
    PGR (Progesterone receptor)
    |
    goserelin acetate
    7d
    A randomized crossover trial on the preference of different preparations of goserelin for androgen deprivation therapy (ADT) in patients with prostate cancer (ChiCTR2500111711)
    P=N/A, N=60, Recruiting, The First Affiliated Hospital of Xiamen University; The First Affiliated Hospital of Xiamen University
    New trial
    |
    goserelin acetate
    7d
    A Multicenter Randomized Controlled Clinical Trial of Neoadjuvant Endocrine Therapy versus Chemotherapy in Patients with HR+/HER2- Early-Stage Breast Cancer (ChiCTR2500111780)
    P4, N=148, Not yet recruiting, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    paclitaxel • cyclophosphamide • Kisqali (ribociclib) • letrozole • epirubicin • goserelin acetate
    7d
    A Phase II, Single-Arm Clinical Study of Goserelin Microspheres for Ovarian Function Preservation During Adjuvant Chemotherapy in Premenopausal Patients with Early Breast Cancer (ChiCTR2500113196)
    P2, N=25, Not yet recruiting, The Third Bethune Hospital of Jilin University; The Third Bethune Hospital of Jilin University
    New P2 trial
    |
    ER (Estrogen receptor)
    |
    ER negative
    |
    goserelin acetate
    7d
    A Single-Arm Phase Ⅱ Clinical Study on the Ovarian Protective Effect of Goserelin Microspheres in Adjuvant Chemotherapy for Premenopausal Patients with Early-Stage Breast Cancer (ChiCTR2500112908)
    P2, N=25, Not yet recruiting, China-Japan Union Hospital of Jilin University; China-Japan Union Hospital of Jilin University
    New P2 trial
    |
    goserelin acetate
    15d
    NePtune: Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (clinicaltrials.gov)
    P2, N=32, Recruiting, Rana McKay, MD | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • RAD54L2 (RAD54 Like 2)
    |
    Lynparza (olaparib) • triptorelin • goserelin acetate • leuprolide acetate for depot suspension
    15d
    Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Xiao X. Wei, MD | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • ABRAXAS1 (Abraxas 1 BRCA1 A Complex Subunit 2) • GEN1 (GEN1 Holliday junction 5' flap endonuclease)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    OncoPanel™ Assay
    |
    Opdivo (nivolumab) • docetaxel • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension
    23d
    PreEMBER: A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer (clinicaltrials.gov)
    P2, N=600, Not yet recruiting, Eli Lilly and Company | Trial completion date: Jan 2029 --> Dec 2029
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative
    |
    tamoxifen • Inluriyo (imlunestrant) • goserelin acetate